Biao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Biao Wang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Liang Li
Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, CA 94304, USA
2 shared publications- Yang Sun
Department of Ophthalmology, Stanford University School of Medicine
2 shared publications - Chien-Hui Lo
Byers Eye Institute, Department of Ophthalmology, Stanford University, Palo Alto, CA 94304, USA
1 shared publication Jorge A Alvarado
Department of Ophthalmology Stanford University School of Medicine Palo Alto CA USA
1 shared publication- Ke Ning
Department of Ophthalmology, Stanford University School of Medicine , 1651 Page Mill Road, Rm 2220, Palo Alto, CA 94304
1 shared publication Lei S. Qi
Department of Bioengineering, Stanford University, Stanford, CA 94305, USA
1 shared publication
Latest Publications
- Open Access
- 20 December 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (51) , eadn7540
dCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa
Retinitis pigmentosa (RP) is characterized by degeneration of rod and cone photoreceptors that progresses to irreversible blindness. Now, there are no mutation-agnostic approaches to treat RP. Here, we utilized a single adeno-associated virus (AAV)–based CRISPR activation system to activate phosphodiesterase 6B (Pde6b) to mitigate the severe degeneration in Pde6a nmf363 mice. We demonstrate that transcriptional activation of Pde6b can rescue the loss of Pde6a , with preservation of retinal structure, restoration of electroretinography responses, and improvement of visual function as assessed by optokinetic response and looming-induced escape behaviors. These findings demonstrate the therapeutic potential of a dCasMINI-mediated activation strategy that provides a mutation-independent treatment for retinal degeneration. This study offers a promising therapeutic approach for RP and potentially other forms of genetic diseases.
- 20 December 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (51) , eadn7540
Open AccessdCasMINI-mediated therapy rescues photoreceptors degeneration in a mouse model of retinitis pigmentosa
Retinitis pigmentosa (RP) is characterized by degeneration of rod and cone photoreceptors that progresses to irreversible blindness. Now, there are no mutation-agnostic approaches to treat RP. Here, we utilized a single adeno-associated virus (AAV)–based CRISPR activation system to activate phosphodiesterase 6B (Pde6b) to mitigate the severe degeneration in Pde6a nmf363 mice. We demonstrate that transcriptional activation of Pde6b can rescue the loss of Pde6a , with preservation of retinal structure, restoration of electroretinography responses, and improvement of visual function as assessed by optokinetic response and looming-induced escape behaviors. These findings demonstrate the therapeutic potential of a dCasMINI-mediated activation strategy that provides a mutation-independent treatment for retinal degeneration. This study offers a promising therapeutic approach for RP and potentially other forms of genetic diseases.
- 13 May 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (7) , e52173
OCRL regulates lysosome positioning and mTORC1 activity through SSX2IP-mediated microtubule anchoring
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 13 May 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (7) , e52173
OCRL regulates lysosome positioning and mTORC1 activity through SSX2IP-mediated microtubule anchoring
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.